Skip to main navigation
Skip to search
Skip to main content
Aston Research Explorer Home
Help & FAQ
Home
Research units
Profiles
Research output
Datasets
Student theses
Activities
Press/Media
Prizes
Equipment
Search by expertise, name or affiliation
Oral antidiabetic agents: Current role in type 2 diabetes mellitus
Andrew J. Krentz
*
,
Clifford Bailey
*
Corresponding author for this work
School of Biosciences
College of Health and Life Sciences
Aston Research Centre for Health in Ageing
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Oral antidiabetic agents: Current role in type 2 diabetes mellitus'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Current Role
100%
Sulfonylurea
100%
Oral Antidiabetic Agents
100%
Metformin
71%
Insulin
57%
Thiazolidinediones
57%
Clinical Trials
57%
United Kingdom Prospective Diabetes Study
57%
Type 2 Diabetic Patients
42%
Hyperglycemia
42%
Biguanides
42%
Vascular Complications
42%
Glycemic Control
28%
Glucose-lowering Drugs
28%
Hemoglobin A1c (HbA1c)
28%
Myocardial Infarction
28%
Tolerability
28%
Main Class
28%
Secretagogue
28%
Initial Treatment
28%
α-glucosidase Inhibitor
28%
Glucose Intolerance
28%
Carbohydrates
14%
Beneficial Effects
14%
Digestion
14%
Insulin Action
14%
Drug Therapy
14%
Weight Gain
14%
Diabetes
14%
Cardiovascular Risk
14%
Monotherapy
14%
Comorbidity
14%
Antidiabetic Drugs
14%
Complex Disorders
14%
Insulin Secretion
14%
Plasma Glucose
14%
Clinical Assessment
14%
Newly Diagnosed Patients
14%
Self-monitoring
14%
Mode of Action
14%
Progression Rate
14%
Long-term Glycaemic Control
14%
Cardiovascular Events
14%
Long-term Treatment
14%
Patient's Will
14%
High-risk Individuals
14%
Overweight or Obesity
14%
Obese Patients
14%
Islet β-cell Function
14%
Cardiovascular Endpoints
14%
Glycemic Stability
14%
Macrovascular Disease
14%
Diabetic Ketoacidosis
14%
Insulin Therapy
14%
Clinical High Risk
14%
Glycated Hemoglobin
14%
Non-pharmacological Measures
14%
Multifactorial Approach
14%
Antidiabetic Agents
14%
Safety Profile
14%
Glycemic Response
14%
Metabolic Syndrome Components
14%
Metabolic Decompensation
14%
Obesity-induced Insulin Resistance
14%
Treatment Choice
14%
Capillary Blood Glucose
14%
Approaches to Management
14%
Rapid-acting
14%
Hepatic Impairment
14%
Working Diagnosis
14%
Difficult-to-treat
14%
Intensive Lifestyle Intervention
14%
Cardiovascular Safety
14%
Normoglycaemia
14%
Safety Considerations
14%
Progressive Disease
14%
Nonketotic
14%
Interventional Clinical Trials
14%
Daily Maximum
14%
Acarbose
14%
Postprandial Hyperglycemia
14%
Hepatic Glucose Production
14%
Overweight Patient
14%
Steno
14%
Oral Antidiabetic Drugs
14%
Oral Antidiabetic Therapy
14%
Pre-diabetes (pre-DM)
14%
Multiple Components
14%
Intercurrent Illness
14%
Renal Impairment
14%
Patient Safety
14%
Expected Effect
14%
Troglitazone
14%
Biochemical Assessment
14%
Insulin Sensitizers
14%
Drug Choice
14%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Oral Antidiabetic Agent
100%
Sulfonylurea
100%
Diabetes
71%
Clinical Trial
71%
Glycon
71%
Thiazolidinedione
57%
Monotherapy
42%
Hyperglycemia
42%
Antidiabetic Agent
42%
Glycemic Control
42%
Cardiovascular System
42%
Patient with Type 2 Diabetes
42%
Disease
28%
Obesity
28%
Myocardial Infarction
28%
Hemoglobin A1c
28%
Secretagogue
28%
Glycemic
28%
Low Drug Dose
28%
Glucose Intolerance
28%
Glucosidase
28%
Biguanide Derivative
28%
Insulin Release
14%
Drug Therapy
14%
Clinician
14%
Insulin Resistance
14%
Biguanide
14%
Cardiovascular Risk
14%
Atherosclerosis
14%
Severe Hepatic Impairment
14%
Acarbose
14%
Macrovascular Disease
14%
Troglitazone
14%
Self Monitoring
14%
Microvascular Complication
14%
Metabolic Syndrome
14%
Capillary Blood
14%
Pancreas Islet Cell Function
14%
Insulin Treatment
14%
Patient Safety
14%
Gluconeogenesis
14%
Blood Glucose
14%
Lifestyle Intervention
14%
Postprandial Hyperglycemia
14%
Glycated Hemoglobin
14%
Diabetic Ketoacidosis
14%
Severe Renal Impairment
14%
Comorbidity
14%
Pharmacology, Toxicology and Pharmaceutical Science
Oral Antidiabetic Agent
100%
Sulfonylurea
100%
Non Insulin Dependent Diabetes Mellitus
100%
Metformin
71%
Clinical Trial
71%
Hyperglycemia
57%
Thiazolidinedione
57%
Disease
42%
Antidiabetic Agent
42%
Monotherapy
42%
Obesity
28%
Hemoglobin A1c
28%
Heart Infarction
28%
Biguanide Derivative
28%
Glucose Intolerance
28%
Tolerability
28%
Glucosidase
28%
Insulin Resistance
14%
Pharmacotherapy
14%
Biguanide
14%
Cardiovascular Risk
14%
Atherosclerosis
14%
Diabetic Ketoacidosis
14%
Glycosylated Hemoglobin
14%
Severe Hepatic Impairment
14%
Acarbose
14%
Severe Renal Impairment
14%
Troglitazone
14%
Metabolic Syndrome X
14%
Comorbidity
14%